SCHEMBL421583

SCHEMBL421583

Cc1nn(-c2ccc(C#N)cc2)c2cccc(-c3cnc4ccccc4c3)c12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 8/20 0.53
NR3C1 P04150 1/20 0.40
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
AR P10275 1/20 0.39
PIK3CA P42336 3/20 0.38
MTOR P42345 3/20 0.38
PIK3CD O00329 2/20 0.37
BRD4 O60885 1/20 0.37
CREBBP Q92793 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP1A2 P05177 1/20 0.36
PDPK1 O15530 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425541 0.85 HSP90AA1 (0.51) HSP90AA1ALDH1A1NPC1MAPTRAB9A
SCHEMBL28798148 0.84 HSP90AA1 (0.47) HSP90AA1ALDH1A1NPC1MAPTRAB9A
SCHEMBL424104 0.82 HSP90AA1 (0.64) HSP90AA1ALDH1A1HPGD
SCHEMBL951110 0.82 HSP90AA1 (0.53) HSP90AA1ALDH1A1NPC1MAPTRAB9A
SCHEMBL421857 0.80 HSP90AA1 (0.51) HSP90AA1NR3C1PIK3CAMTORPIK3CD
SCHEMBL1394528 0.80 HSP90AA1 (0.52) HSP90AA1
SCHEMBL418796 0.79 HSP90AA1 (0.53) HSP90AA1AR
SCHEMBL1394538 0.79 HSP90AA1 (0.53) HSP90AA1ALDH1A1KDM4EGAAHPGD
SCHEMBL947823 0.78 PIK3CA (0.40) HSP90AA1ALDH1A1NPC1MAPTRAB9A
SCHEMBL1394276 0.77 HSP90AA1 (0.51) HSP90AA1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102439003-A Indazole derivatives inhibiting HSP90, compositions containing said derivatives and uses thereof SANOFI AVENTIS 2012-05-02 CN disclosed
EP-2408762-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI (FR) 2012-01-25 EP disclosed
US-20120010241-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI (FR) 2012-01-12 US disclosed
WO-2010106290-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI-AVENTIS (FR) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010241-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF HSP90AB2P, HSP90AB1, HSP90AA1 HSP90AA1 3/4885NR3C1 34/4885ALDH1A1 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.